SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 9,341.87 |
| Enterprise Value ($M) | 8,173.27 |
| Book Value ($M) | 1,664.23 |
| Book Value / Share | 22.06 |
| Price / Book | 5.61 |
| NCAV ($M) | 1,552.89 |
| NCAV / Share | 20.59 |
| Price / NCAV | 6.02 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.21 |
| Return on Assets (ROA) | -0.33 |
| Return on Equity (ROE) | -0.37 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | 18.21 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,716.62 |
| Assets | 1,827.97 |
| Liabilities | 163.73 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -354.44 |
| Net Income | -348.87 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | -5.29 |
| Earnings Per Share Basic | -5.29 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -238.37 |
| Cash from Investing | -541.17 |
| Cash from Financing | -541.17 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Versant Ventures IV, LLC | 1.90 | ||
| 13G/A | ARK Investment Management LLC | 14.62 | 23.12 | |
| 13G/A | Capital International Investors | 10.70 | 1.42 | |
| 13G/A | Nikko Asset Management Americas, Inc. | 5.39 | 25.82 | |
| 13G/A | Sumitomo Mitsui Trust Holdings, Inc. | 5.39 | 25.80 | |
| 13D/A | Versant Venture Capital IV, L.P. | 3.00 | -7.33 | |
| 13D/A | Glaxosmithkline Plc | 4.80 | 0.46 | |
| 13G/A | Vertex Pharmaceuticals Inc / Ma | 4.40 | -50.00 | |
| 13D/A | Bayer Global Investments B.v. | 4.90 | -19.87 | |
| 13G/A | New Enterprise Associates 15, L.P. | |||
| 13D/A | Celgene Corp /de/ | 6.10 | -15.30 | |
| 13D/A | Abingworth LLP | 4.00 | -12.07 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| Annual Report – 10-K | ||
| Quarterly Report – 10-Q | ||
| Quarterly Report – 10-Q | ||
| Quarterly Report – 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 131,162 | 882,196 | 14.87 | |
| 343,038 | 1,910,653 | 17.95 | |
| 191,078 | 1,352,750 | 14.13 | |
| 191,464 | 1,080,902 | 17.71 | |
(click for more detail) |
|||
(click for list of largest short owners) |
|||
| Similar Companies | |
|---|---|
| CRMD – CorMedix Inc. | CRNX – Crinetics Pharmaceuticals Inc |
| CRON – Cronos Group Inc. | CRTX – Cortexyme Inc |
| CRVS – Corvus Pharmaceuticals Inc |
Financial data and stock pages provided by
Fintel.io